The stock price performance this year has been a mixed bag, which means people have different opinions about whether it’s been good or bad. Some may see it as optimistic, while others may view it as pessimistic. Year to date metric has recorded a gain of 33.33%.However, over the last six months, we can see a weaker performance of 10.31%. Over the last 30 days, the price of ALLO has leaped by -7.16%. And in the last five days, it has fallen by -23.16%.
Allogene Therapeutics Inc had a pretty Dodgy run when it comes to the market performance. Over the past year, the company’s stock reached a high of $6.89 on 05/15/23, while the lowest price during the same period was $2.23 on 12/01/23.
52-week price history of ALLO Stock
The history of a stock’s 52-week high and low prices can provide important information about its current state and future potential. Allogene Therapeutics Inc’s current trading price is -37.88% away from its 52-week high, while its distance from the 52-week low is 91.93%. The stock’s price range for this period has been between $2.23 and $6.89. The Healthcare sector company’s shares saw a trading volume of about 1.37 million for the day, which was lower than the average daily volume of 2.98 million over the last three months.
The Connection Between Financial Performance and Market Capitalization
Allogene Therapeutics Inc (ALLO) has experienced a quarterly rise of 81.36% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 720.24M and boasts a workforce of 361 employees.
How Moving Averages and Trading Volume Data Work Together
Based on Barchart.com data, the company’s moving average over the 100-day period was 3.46, with a change in price of +1.38. Similarly, Allogene Therapeutics Inc recorded 2,708,643 in trading volume during the last 100 days, posting a change of +46.14%.
ALLO’s Debt-to-Equity Ratio: A Comprehensive Review
A key metric for assessing a company’s financial well-being and market status is the debt-to-equity (D/E) ratio. This ratio is derived by dividing a company’s total liabilities by its shareholders’ equity, and it demonstrates the level of debt a company uses to support its assets relative to shareholder equity. At the time of writing, the total D/E ratio for ALLO stands at 0.17. Similarly, the long-term debt-to-equity ratio is also 0.15.
ALLO Stock Stochastic Average
As of today, the raw stochastic average of Allogene Therapeutics Inc over the past 50 days is 55.13%. This is a increase compared to the raw stochastic average of the last 20 days, which was recorded at 8.09%. Additionally, the Stochastic %K and %D values for the company were 31.18% and 44.34%, respectively, over the past 20 days.
